Aravive Inc

Aravive — Technical Presentation (February 2019)

68 slides from Aravive's technical presentation, Feb 5, 2019

  1. Slide 1: Aravive GAS6/AXL Key Opinion Leader Symposium

    Aravive GAS6/AXL Key Opinion Leader Symposium February 5th, 2019 Exhibit 99.1

  2. Slide 2: Important Information: Forward-Looking Statements

    Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally i

  3. Slide 3: Agenda

    Agenda Welcome - Jay Shepard, CEO History of Axl, Mer and Tyro3 (TAMS) and GAS6/AXL pathway - Greg Lemke, PhD GAS6/AXL Landscape & AVB-S6-500 - Amato Giaccia, PhD, Aravive Co-Founder, Director GAS6/AXL Role in Gynecological Oncology and Other Cancers – Katherine Fuh, PhD, MD AVB-S6-500 Clinical Over

  4. Slide 4: Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway

    Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway Greg Lemke, PhD

  5. Slide 5: All the kinases

    All the kinases

  6. Slide 6: TAMs among the tyrosine kinases

    TAMs among the tyrosine kinases

  7. Slide 7: TAMs and their ligands

    TAMs and their ligands cell 2 oy Ca? ions: PtdSer | Gla |Ligand |. ECF) G56 Igt sHac |Pros1 TaM| FN1 Tes FN2 Mer | ™ Tats cell 1

  8. Slide 8: TAM biology

    TAM biology invireo Review wicey EEE TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy Yemsratch T.Akalu* | Carla V. Rothlin'? | Sourav Ghosh* REVIEWS I The TAM family: phosphatidylserine- sensing receptor tyrosine kinases gone awry in cancer c

  9. Slide 9: TAM biology cancer virus infection

    TAM biology cancer virus infection

  10. Slide 10: TAM biology cancer viral infection vascular biology

    TAM biology cancer viral infection vascular biology

  11. Slide 11: TAM biology cancer viral infection vascular biology immune regulation

    TAM biology cancer viral infection vascular biology immune regulation

  12. Slide 12: Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway

    Axl, Mer and Tyro3 (TAMS) and the GAS6/AXL pathway Greg Lemke, PhD

  13. Slide 13: GAS6/AXL Development Landscape and AVB-S6-500

    Amato J. Giaccia, PhD, Aravive Co-founder, Director GAS6/AXL Development Landscape and AVB-S6-500

  14. Slide 14: GAS6/AXL: Multiple Clinical Applications

    GAS6/AXL: Multiple Clinical Applications

  15. Slide 15: Few Drugs Specifically Target the Metastatic Tumor In Its Microenvironment

    Few Drugs Specifically Target the Metastatic Tumor In Its Microenvironment 6 Source: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology Tumor micro environment drugs include anti-angiogenic agents Avastin and Zaltrap Metastatic Disease Remains The Largest &

  16. Slide 16: Attributes of Key Microenvironment Factor Pathways

    Attributes of Key Microenvironment Factor Pathways VEGF/VEGFR signaling: VEGF source: tumor cells, fibroblasts, and macrophages angiogenesis, vasculogenesis, and lymphangiogenesis Approved drugs: bevacizumab, sunitinib, sorafinib, pegaptinib, ranibizumab, ramucirumab PDL-1/PDL-1 signaling: PDL-1 sou

  17. Slide 17: GAS6/AXL Target Rationale

    Survival & Proliferation Single agent anti-tumor activity Epithelial-Mesenchymal Transition Tumor Adaptation Mechanism EMT is natural cellular survival program that is harnessed by cancer cells in response to a hostile tumor microenvironment with critical role in several aspects of tumor biology Reg

  18. Slide 18: GAS6/AXL Signaling: A Compelling Anticancer Target

    GAS6/AXL Signaling: A Compelling Anticancer Target Activated In Many Different Human Tumors Examples AXL/GAS6 Up-Regulation References AML, CML* >35% Rochlitz et al., 1999 Gioia et al., 2011 Pancreas* 50-70% Song et al., 2011 Koorstra et al., 2009 Ovarian* 50-90% Rankin et al., 2010 Sun et al., 2004

  19. Slide 19: Therapeutic Approaches to Targeting AXL/GAS6

    Therapeutic Approaches to Targeting AXL/GAS6 Small Molecule against AXL Pros: direct anti-tumor activity, known chemistry (kinase inhibitors) Cons: selectivity/specificity challenge due to high kinase homology, off target DLT’s, high attrition for SM development, potential for multiple resistance me

  20. Slide 20: Small molecule drugs with AXL inhibitory activity

    Small molecule drugs with AXL inhibitory activity Cabozantinib (Exelixis) c-Met, VEGFR2, AXL, Ret, Kit, Flt-1/3/4, Tie2 Approved for medullary thyroid and renal cancer NSCLC, bladder, pancreatic neuroendocrine, endometrial, GIST, breast, sarcomas, CRC, HCC (phases 1-3) BGB324 (BerGenBio) AXL, Abl, M

  21. Slide 21: Receptor Antibodies And Antibody-drug Conjugates Targeting GAS6/AXL

    Receptor Antibodies And Antibody-drug Conjugates Targeting GAS6/AXL Compound Sponsor/developer Mechanism YW327.6S2 Genentech Binds to AXL, downregulating AXL expression, inhibiting activation, signalling, and Gas6-dependent Baf3-AXL cell proliferation Anti-AXL D9 and E8 Institut de Recherche en Canc

  22. Slide 22: AVB-S6-500: A Highly Potent Well Characterized Development Candidate

    AVB-S6-500: A Highly Potent Well Characterized Development Candidate Soluble hAXL receptor fused to hIgG1 Fc Clinically validated approach to achieve good PK properties and to reduce clinical/regulatory risk Fc portion same as on marketed drugs (e.g. Zaltrap, Orencia) Human fusion protein to avoid i

  23. Slide 23: AVB-S6-500 MOA: Prevents Binding of GAS6 to AXL

    Nature Chemical Biology, Kariolis, et. al. Natural Affinity: > 30 pM AVB-S6-500 MOA: Prevents Binding of GAS6 to AXL on Cell Membrane and Blocks AXL Signaling GAS6 Axl Aravive-S6 decoy pAXL Aravive-S6 Affinity: < 0.15 pM

  24. Slide 24: AXL Inhibition by AVB-S6-500 is Selective and Potent in Preclinical Studies

    AXL Inhibition by AVB-S6-500 is Selective and Potent in Preclinical Studies AVB-S6-500 BGB324 Foretinib In vivo activity Breast cancer lung metastasis AVB-S6 Radiance [x106] (p/sec/cm2/sr) J Clin Invest. 2017;127(1):183–198

  25. Slide 25: Efficacy - Affinity Matters

    *Established Metastatic Disease **Methods in Rankin et al 2012 Methodology for Ovarian Tumor Model with Established Metastatic Disease** Unpublished “Affinity Matters” Efficacy - Affinity Matters

  26. Slide 26: Potential for Complementary or Companion Diagnostic: A Proprietary Biomarker Assay

    Potential for Complementary or Companion Diagnostic: A Proprietary Biomarker Assay (1) the ability to measure free Gas6 as a proxy of drug activity in the clinical setting (2) The potential to pre-screen for responder populations to improve chances of success (both in oncology and non-oncology clini

  27. Slide 27: Differentiation & Key Advantages of Targeting AXL Signaling Through GAS6 Inactivation

    Differentiation & Key Advantages of Targeting AXL Signaling Through GAS6 Inactivation with Aravive-S6 Improved specificity over small molecule RTK inhibitors RTKs have difficulty obtaining specificity because of kinase homology Multi-kinase inhibitors tend to have exposure limiting side-effects SM m

  28. Slide 28: GAS6 Within the Tumor Microenvironment and Fibrotic Tissue

    GAS6 Within the Tumor Microenvironment and Fibrotic Tissue

  29. Slide 29: GAS6/AXL Stimulates Cancer Growth, Survival and Metastasis: A Key EMT Regulator

    GAS6/AXL Stimulates Cancer Growth, Survival and Metastasis: A Key EMT Regulator

  30. Slide 30: GAS6/AXL Development Landscape and AVB-S6-500

    Amato J. Giaccia, PhD, Aravive Co-founder, Director GAS6/AXL Development Landscape and AVB-S6-500

  31. Slide 31: GAS6/AXL Role in Gynecological Oncology and Other Cancers

    GAS6/AXL Role in Gynecological Oncology and Other Cancers Katherine Fuh, MD, PhD

  32. Slide 32: How AXL is Important in Cancer

    How AXL is Important in Cancer CANCER IS METASTATIC RELAPSES CHEMORESISTANT NEED TREATMENT THAT ATTACKS ALL THESE STEPS

  33. Slide 33: AXL Is Critical in Renal Cell, Breast, and Liver Cancer Metastasis

    AXL Is Critical in Renal Cell, Breast, and Liver Cancer Metastasis

  34. Slide 34: AXL Is Critical in Ovarian and Uterine Cancer Metastasis

    AXL Is Critical in Ovarian and Uterine Cancer Metastasis

  35. Slide 35: AXL Regulates Treatment Resistance in Ovarian, Uterine, Renal Cell and Lung Cancer

    AXL Regulates Treatment Resistance in Ovarian, Uterine, Renal Cell and Lung Cancer

  36. Slide 36: Original articles on AXL and resistance to therapy

    ORIGINAL ARTICLE Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma L Zhou', X-D Liu', M Sun’, X Zhang’, P German’, S Bai’, Z Ding’, N Tannir', CG Wood?, SF Matin?, JA Karam?, P Tamboli®, K Sircar?, P Rao®, EB Rankin‘, DA Laird®, AG Hoang’, CL Walker®, AJ Giaccia

  37. Slide 37: Treatment Paradigm for Ovarian Cancer

    Treatment Paradigm for Ovarian Cancer Progression Secondary Diagnosis surgery? ! Chemo ' Chemo Chemo Chemo | Symptoms — #1 -F Maintenance A, = — a2 cee) iia: | C it Death joncomitant \4 Supportive / Staging/debulking care

  38. Slide 38: Need: Anti-metastasis agent and chemotherapy-sensitizing agent

    Need: 1) Anti-metastasis agent 2) Chemotherapy-sensitizing agent

  39. Slide 39: AXL is increased post-chemotherapy in tumors that did not respond

    Post-chemotherapy - Biopsy Pre-chemotherapy Biopsy NED NED NED DOD AXL is increased post-chemotherapy in tumors that did not respond

  40. Slide 40: Elevated tumor GAS6 and AXL in chemoresistant ovarian cancer

    Elevated tumor GAS6 and AXL in chemoresistant ovarian cancer AXL GAS6

  41. Slide 41: Elevated serum GAS6 in chemoresistant ovarian cancer

    Elevated serum GAS6 in chemoresistant ovarian cancer

  42. Slide 42: AXL expression correlates with chemoresistance to carboplatin and paclitaxel

    AXL expression correlates with chemoresistance to carboplatin and paclitaxel

  43. Slide 43: AVB-S6-500 in combination with chemotherapy prevents cell growth

    AVB-S6-500 in combination with chemotherapy prevents cell growth

  44. Slide 44: AVB-S6-500 in combination with chemo inhibits tumor growth

    AVB-S6-500 in combination with chemo inhibits tumor growth PDX model OVCAR8 model

  45. Slide 45: Maintenance AVB-S6-500 continues to maintain low tumor volume

    Maintenance AVB-S6-500 continues to maintain low tumor volume

  46. Slide 46: AXL is highly expressed in ovarian cancer

    AXL is highly expressed in ovarian cancer No Expression Low Moderate - High Total specimens Normal ovary n=10 (100%) n=10 High-grade serous ovarian n=14 (9%) n=6 (4%) n=139 (87%) n=159 Omentum n=3 (9%) n=5 (16%) n=24 (75%) n=32 Peritoneum 1 (3%) 2 (7%) 27 (90%) n=30

  47. Slide 47: GAS6/AXL Role in Gynecological Oncology and Other Cancers

    GAS6/AXL Role in Gynecological Oncology and Other Cancers Katherine Fuh, MD, PhD

  48. Slide 48: AVB-S6-500 in IgA Nephropathy

    AVB-S6-500 in IgA Nephropathy Gail McIntyre, PhD, DABT Aravive SVP R&D

  49. Slide 49: IgA Nephropathy: Potentially Accelerated Development Pathway

    IgA Nephropathy: Potentially Accelerated Development Pathway Most common cause of Primary Glomerulonephritis and responsible for 10% of patients on dialysis Approximately 150,000-180,000 people in the US IgAN is caused by IgA deposits in the kidneys, causing mesangial proliferation (proteinuria) and

  50. Slide 50: Decreased Proteinuria Improves Survival in IgAN

    Decreased Proteinuria Improves Survival in IgAN Proteinuria in IgAN patients is associated with renal outcomes and the degree of proteinuria is the best predictor of renal risk 28 Effect of Proteinuria on Renal Survival in IgA Nephropathy Survival from renal failure <0.3 g/day 0.3-1g/day 1-2 g/day 2

  51. Slide 51: GAS6 is expressed in IgAN

    GAS6 is expressed in IgAN Control (6 cases) Epithelial type (28 cases) Endo/mes type (3 cases) a - ’ . y A B Cc § : Figure 1. in human IgA th . p with anti shown in (A) (6) from | ar tally and (0 from | ion nephropathy cases mnmunostained in endothellal and mesangial cells The original magnification

  52. Slide 52: GAS6 Expression Correlates with Severity of IgA Nephropathy

    GAS6 Expression Correlates with Severity of IgA Nephropathy

  53. Slide 53: Aravive Data: Serum GAS6 Elevated in IgA Patients

    Aravive Data: Serum GAS6 Elevated in IgA Patients

  54. Slide 54: Lower Affinity GAS6-trap Improves Fibrosis and Proteinuria in Preclinical Glomerulonephritis

    Lower Affinity GAS6-trap Improves Fibrosis and Proteinurea in Preclinical Experimental Glomerulonephritis

  55. Slide 55: High Level Development Plan

    High Level Development Plan Small (N of 10-12) IgAN patients treated for 2 mos (4 doses) Open-label Monitor safety, PK/PD Ensure sGAS6 levels suppressed over dosing interval Monitor proteinuria, hematuria and other renal functions Biopsy prior and after treatment to assess effect on renal tissue and

  56. Slide 56: AVB-S6-500 in IgA Nephropathy

    AVB-S6-500 in IgA Nephropathy Gail McIntyre, PhD, DABT Aravive SVP R&D

  57. Slide 57: Aravive Clinical Development Program

    Aravive Clinical Development Program Gail McIntyre, PhD, DABT Aravive SVP R&D

  58. Slide 58: Why Platinum-Resistant Ovarian Cancer as First Indication?

    Why Platinum-Resistant Ovarian Cancer as First Indication? Wealth of preclinical data with AVB-S6-500 in platinum resistant ovarian cancer Platinum-resistant ovarian tumors are highly AXL positive High unmet medical need mPFS for platinum resistant patients given paclitaxel or doxil is 3mos with OS

  59. Slide 59: First Clinical Study in Healthy Volunteers

    First Clinical Study in Healthy Volunteers Identified Well-Tolerated and Pharmacologically Active Doses 1 mg/kg 2.5 mg/kg 5 mg/kg 10 mg/kg 5 mg/kg weekly x 4 weeks Single Ascending IV Dose Portion Single-blind, Randomized 6 active/2 placebo per dose Repeat IV Dose Portion Single-blind, Randomized 7

  60. Slide 60: All Doses of AVB-S6-500 Were Well-Tolerated

    All Doses of AVB-S6-500 Were Well-Tolerated AVB-S6-500 was well-tolerated across all doses (1-10mg/kg single doses and 4 weekly 5mg/kg doses) Treatment-emergent adverse events generally mild, transient and self-limiting No serious adverse events reported No anti-drug antibodies noted

  61. Slide 61: Proof of Mechanism Demonstrated At All Doses

    Proof of Mechanism Demonstrated At All Doses Increased AVB-S6-500 Dose Increased Duration of Abrogation of Serum GAS6

  62. Slide 62: Platinum Resistant Ovarian Cancer Phase 1b/2: Phase 1b Portion

    Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 1b Portion Safety lead-in portion of the Phase 1b/2 trial is designed to confirm dose predicted based on Phase 1 study in healthy volunteers Primary objective to assess safety and tolerability; Secondary objective to assess PK/PD and

  63. Slide 63: Platinum Resistant Ovarian Cancer Phase 1b/2: Phase 2 Portion

    Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 2 Portion Anticipated Phase 2 Trial Design Status: FPI expected 2H19, topline data expected end of 2020 Total N = 120 Platinum Resistant Ovarian Cancer 1-3 prior lines AVB-S6-500 + Pac N = 40 AVB-S6-500 + PLD N = 40 Pac N = 20 PLD N =

  64. Slide 64: Next Oncology Study: Clear Cell Renal Cell Carcinoma (ccRCC)

    Next Oncology Study: Clear Cell Renal Cell Carcinoma (ccRCC) Unmet medical need Kidney cancer is a leading cause of cancer-related deaths in the United States. Metastasis to distant organs including the lung, bone, liver, and brain is the primary cause of death in kidney cancer patients, as only 12%

  65. Slide 65: Rationale for AVB-S6-500 as Treatment for ccRCC

    Rationale for AVB-S6-500 as Treatment for ccRCC AXL is increased and activated in response to low oxygen tensions AXL mediates prometastatic behavior in renal cell carcinoma and hepatocellular carcinoma cells under certain conditions AXL plays an important role in both EMT. Inhibition of AXL reverse

  66. Slide 66: Aravive Clinical Development Program

    Aravive Clinical Development Program Gail McIntyre, PhD, DABT Aravive SVP R&D

  67. Slide 67: Q&A?

    ¢°3 aravive Q&A?

  68. Slide 68: Thank you

    ¢°3 aravive Thank you

Aravive — Technical Presentation (February 2019) on 6ix